Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02218879 · ClinicalTrials.gov registry record
Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS
A clinical trial, sponsored by Yale University.
- Terminated
- Registry status
- 7
- Enrollment target
NCT02218879 is a clinical trial that was terminated before completion, run by Yale University. The registered enrollment target is 7 participants.
The verdict
NCT02218879 was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- 7 participants
- Enrollment target
Study Summary
The primary objective is to directly estimate brain glutathione concentrations in vivo using H-MRS at 7T before and after initiation of Tecfidera in established multiple sclerosis (MS) patients considering switching therapy or being treatment-naive (first line).
Interventions
- DRUG Tecfidera
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2014-08 |
| Est. Completion | 2016-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02218879
The ClinicalTrials.gov registry entry for NCT02218879 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tecfidera is the first listed.
NCT02218879 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02218879 about?
NCT02218879 is a clinical study titled "Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS". The primary objective is to directly estimate brain glutathione concentrations in vivo using H-MRS at 7T before and after initiation of Tecfidera in established multiple sclerosis (MS) patients considering switching therapy or being treatment-naive (first line).
What is the current status of trial NCT02218879?
This trial is currently terminated. The enrollment target is 7 participants. The study started on 2014-08. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02218879?
The interventions under investigation include: Tecfidera (DRUG).
Who is sponsoring clinical trial NCT02218879?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.